Dyadic International (DYAI) EBT Margin (2018 - 2026)
Dyadic International (DYAI) posted EBT Margin of 175.28% for Q1 2026, down 295.78% sequentially from 89.53% in Q4 2025, and up 33827.0% YoY from N/an in Q1 2025.
Dyadic International (DYAI) EBT Margin (2018 - 2026) Analysis & Trends
Dyadic International has reported EBT Margin for 9 years, with the latest figure at 175.28% in Q1 2026.
- Quarterly EBT Margin rose 33827.0% year-over-year to 175.28% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 441.99% (down 28134.0% YoY) and the FY2025 annual result came in at 2826.94%, down 216647.0% from the prior year.
- EBT Margin declined to 175.28% in Q1 2026 per DYAI's latest filing, from 89.53% in the prior quarter.
- Over five years, EBT Margin peaked at 89.53% in Q4 2025 and troughed at 1128.45% in Q2 2022.
- A 5-year average of 368.91% and a median of 299.46% in 2022 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2024: EBT Margin jumped 372829 bps in 2022, then tumbled 35089 bps in 2024.
- Over 5 years, EBT Margin stood at 302.88% in 2022, then gained by 0 bps to 301.78% in 2023, then surged by 36 bps to 193.48% in 2024, then jumped by 146 bps to 89.53% in 2025, then tumbled by 296 bps to 175.28% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 175.28%, 89.53%, and 167.25% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | Dyadic International | 20.18 Mn | 20.18 Mn | - | -171.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -175.28% |
| Dec 31, 2025 | 89.53% |
| Sep 30, 2025 | -167.25% |
| Jun 30, 2025 | -195.41% |
| Mar 31, 2025 | -513.55% |
| Dec 31, 2024 | -193.48% |
| Sep 30, 2024 | -9.72% |
| Jun 30, 2024 | -496.85% |
| Mar 31, 2024 | -615.56% |
| Dec 31, 2023 | -301.78% |
| Sep 30, 2023 | -406.55% |
| Jun 30, 2023 | -260.55% |
| Mar 31, 2023 | -264.66% |
| Dec 31, 2022 | -302.88% |
| Sep 30, 2022 | -299.46% |
| Jun 30, 2022 | -1,128.45% |
| Mar 31, 2022 | -1,029.62% |
| Dec 31, 2021 | -4,031.16% |
| Sep 30, 2021 | -2,289.11% |
| Jun 30, 2021 | -1,049.23% |